Kenjiro Kimura

Kenjiro Kimura

Auto-generated profile, based on publicly available information

Kenjiro Kimura

St. Marianna University School of Medicine

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2011 in Diabetes Care
Verified
Journal Article
Open access
PDF file
AKAtsuko Kamijo-Ikemori
Atsuko Kamijo-Ikemori
TSTakeshi Sugaya
Takeshi Sugaya
TYTakashi Yasuda
Takashi Yasuda
TKTakehiro Kawata
Takehiro Kawata
AOAkio Ota
Akio Ota
KKKenjiro Kimura
Kenjiro Kimura
OBJECTIVE Urinary liver-type fatty acid–binding protein (L-FABP) is a promising indicator of tubular but not glomerular damage. The aim of this study was to evaluate the clinical usefulness of urinary L-FABP as a prognostic biomarker in impaired diabetic nephropathy in type 2 diabetes. RESEARCH DESIGN AND METHODS This investigation involved a cross-sectional and longitudinal analysis of the relationship between urinary L-FABP levels and progressive nephropathy. Urinary L-FABP was measured with enzyme-linked immunosorbent assay. In the cross-sectional analysis, the association of urinary L-FABP, with the severity of diabetic nephropathy, was investigated in 140 patients with type 2 diabetes and in 412 healthy control subjects. Of the patients in the former study, 104 have been followed for 4 years. The progression of diabetic nephropathy was defined as progressive albuminuria, end-stage renal disease, or induction of hemodialysis. RESULTS Urinary L-FABP levels were progressively increased in subjects with normo-, micro-, or macroalbuminuria and further increased in patients with end-stage renal disease. In the longitudinal analysis, high urinary L-FABP levels were associated with the increase in albuminuria, progression to end-stage renal disease, or induction of hemodialysis. This was particularly demonstrated in the subgroup of patients without renal dysfunction (n = 59), where high urinary L-FABP levels were associated with the progression of diabetic nephropathy. CONCLUSIONS Urinary L-FABP accurately reflected the severity of diabetic nephropathy in type 2 diabetes, and its level was high in the patients with normoalbuminuria. Moreover, higher urinary L-FABP was a risk factor for progression of diabetic nephropathy.

11 March 2006 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
AKAtsuko Kamijo
Atsuko Kamijo
TSTakeshi Sugaya
Takeshi Sugaya
AHAkihisa Hikawa
Akihisa Hikawa
MYMasaya Yamanouchi
Masaya Yamanouchi
YHYasunobu Hirata
Yasunobu Hirata
KKKenjiro Kimura
Kenjiro Kimura

16 January 2014 in Trials
Verified
Journal Article
Open access
PDF file
THTatsuo Hosoya
Tatsuo Hosoya
KKKenjiro Kimura
Kenjiro Kimura
Sadayoshi ItoSadayoshi Ito
Sadayoshi Ito
MIMasaaki Inaba
Masaaki Inaba
SUShunya Uchida
Shunya Uchida
HHHiroshi Hayakawa
Hiroshi Hayakawa
Hyperuricemia is a risk factor for the onset of chronic kidney disease (CKD) and is significantly associated with the progression of CKD. However, there is no sufficient evidence by interventional research supporting a cause-effect relationship. Hyperuricemic patients without gouty arthritis, whose serum urate (SUA) concentration is ≥8.0 mg/dL and who have a complication, are treated by pharmacotherapy in addition to lifestyle guidance. Nevertheless, there is no evidence that rationalizes pharmacotherapy for patients with hyperuricemia who have no complication and whose SUA concentration is below 9.0 mg/dL.

1 March 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
KMKatsuomi Matsui
Katsuomi Matsui
AKAtsuko Kamijo-Ikemorif
Atsuko Kamijo-Ikemorif
TSTakeshi Sugaya
Takeshi Sugaya
TYTakashi Yasuda
Takashi Yasuda
KKKenjiro Kimura
Kenjiro Kimura

19 April 2011 in Nephrology
Verified
Journal Article
Open access
PDF file
AKAtsuko Kamijo‐Ikemori
Atsuko Kamijo‐Ikemori
TSTakeshi Sugaya
Takeshi Sugaya
KMKatsuomi Matsui
Katsuomi Matsui
TYTakeshi Yokoyama
Takeshi Yokoyama
KKKenjiro Kimura
Kenjiro Kimura
Kidney disease develops to renal failure over a period of days, months or years, hence, clinical markers that indicate the real‐time renal pathophysiological conditions is important. Liver type fatty acid binding protein (L‐FABP) is a 14 kDa molecule predominantly expressed in human proximal tubules. Clinical studies demonstrate that urinary excretion of L‐FABP derived from the proximal tubules is an excellent biomarker for predicting and monitoring deterioration of renal function or for early detection of kidney disease. However, in order to clarify the pathophysiological roles or dynamics of renal L‐FABP in diseased settings, in vivo experimental studies of kidney diseases are indispensable. Since L‐FABP is not endogenously expressed in murine kidneys, a transgenic (Tg) mouse model with expression of the human L‐FABP gene was established. This review article summarizes the findings on the pathophysiological roles and dynamics of renal human L‐FABP in the recent experimental studies performed using this Tg mouse model.

14 December 2010 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
KMKatsuomi Matsui
Katsuomi Matsui
AKAtsuko Kamijo-Ikemori
Atsuko Kamijo-Ikemori
MHMasanori Hara
Masanori Hara
TSTakeshi Sugaya
Takeshi Sugaya
TKTakamitsu Kodama
Takamitsu Kodama
KKKenjiro Kimura
Kenjiro Kimura